CR8931A - Benzoxazoles sustituidos con profarmaco como agentes estrogenicos - Google Patents

Benzoxazoles sustituidos con profarmaco como agentes estrogenicos

Info

Publication number
CR8931A
CR8931A CR8931A CR8931A CR8931A CR 8931 A CR8931 A CR 8931A CR 8931 A CR8931 A CR 8931A CR 8931 A CR8931 A CR 8931A CR 8931 A CR8931 A CR 8931A
Authority
CR
Costa Rica
Prior art keywords
profarmaco
strogen
benzoxazoles
agents
replaced
Prior art date
Application number
CR8931A
Other languages
English (en)
Inventor
Sayed Elmarakby
Ping Cai
Appavu Chandrasekaran
Mark Ruppen
Rasmy Talaat
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of CR8931A publication Critical patent/CR8931A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
    • C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
    • C07D263/56—Benzoxazoles; Hydrogenated benzoxazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D263/57—Aryl or substituted aryl radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/423—Oxazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Reproductive Health (AREA)
  • Rheumatology (AREA)
  • Toxicology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Gynecology & Obstetrics (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)

Abstract

Esta invencion provee moduladores del receptor de estrogeno de formula I, que tienen la estructura (I) en donde Q1, Q2, R1, R2, R2a, R3, R3a, y X como se definen en la especificacion, o una sal farmaceuticamente aceptable del mismo.
CR8931A 2004-08-26 2007-02-15 Benzoxazoles sustituidos con profarmaco como agentes estrogenicos CR8931A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US60483504P 2004-08-26 2004-08-26

Publications (1)

Publication Number Publication Date
CR8931A true CR8931A (es) 2007-08-28

Family

ID=35750972

Family Applications (1)

Application Number Title Priority Date Filing Date
CR8931A CR8931A (es) 2004-08-26 2007-02-15 Benzoxazoles sustituidos con profarmaco como agentes estrogenicos

Country Status (22)

Country Link
US (2) US20060046968A1 (es)
EP (1) EP1781628A2 (es)
JP (1) JP2008510827A (es)
KR (1) KR20070046148A (es)
CN (1) CN101044126A (es)
AR (1) AR050618A1 (es)
AU (1) AU2005280178A1 (es)
BR (1) BRPI0514628A (es)
CA (1) CA2576353A1 (es)
CL (1) CL2008000506A1 (es)
CR (1) CR8931A (es)
EC (1) ECSP077279A (es)
GT (1) GT200500228A (es)
IL (1) IL181236A0 (es)
MX (1) MX2007002251A (es)
NI (1) NI200700055A (es)
NO (1) NO20071159L (es)
PE (1) PE20060503A1 (es)
RU (1) RU2007105232A (es)
SV (1) SV2006002205A (es)
TW (1) TW200612925A (es)
WO (1) WO2006026316A2 (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA83620C2 (ru) * 2001-12-05 2008-08-11 Уайт Замещенные бензоксазолы и их аналоги как эстрогенные агенты
WO2007103869A2 (en) * 2006-03-06 2007-09-13 Wyeth Liquid and semi-solid pharmaceutical formulations and processes
WO2008057309A2 (en) * 2006-11-02 2008-05-15 Merck & Co., Inc. Estrogen receptor modulators
PE20081302A1 (es) * 2006-11-30 2008-10-17 Wyeth Corp Proceso para la sintesis de derivados monosulfatados de benzoxazoles sustituidos
PE20081502A1 (es) * 2006-11-30 2008-11-24 Wyeth Corp Proceso para la sintesis de derivados monosulfatados de benzoxazoles sustituidos
US20090010884A1 (en) * 2007-07-06 2009-01-08 Wyeth Pharmaceutical compositions and methods of preventing, treating, or inhibiting inflammatory diseases, disorders, or conditions of the skin, and diseases, disorders, or conditions associated with collagen depletion
JP2011511803A (ja) * 2008-02-08 2011-04-14 ワイス・エルエルシー 置換ベンゾオキサゾールのホスファート誘導体
EP2350032B1 (en) * 2008-09-26 2016-05-25 Eisai R&D Management Co., Ltd. Benzoxazole compounds and methods of use
WO2010036908A1 (en) * 2008-09-26 2010-04-01 Eisai R & D Management Co., Ltd. Use of benzoxazole compounds in the treatment of malaria
WO2010083220A1 (en) 2009-01-19 2010-07-22 Abbott Laboratories Benzoxazole inhibitors of poly(adp-ribose)polymerase
KR20160007029A (ko) 2014-07-10 2016-01-20 삼성전기주식회사 압전 소자 및 이를 포함하는 압전 진동 모듈
WO2016136727A1 (ja) * 2015-02-24 2016-09-01 国立大学法人鳥取大学 認知症の予防及び／又は治療のための医薬
CN117045680B (zh) * 2023-10-12 2023-12-08 北京国卫生物科技有限公司 促进肝脏再生的干细胞制剂及其制备方法

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SU600138A1 (ru) * 1976-06-25 1978-03-30 Ленинградский Технологический Институт Имени Ленсовета Способ получени оксипроизводных 2-арилбензазолов
US4418068A (en) * 1981-04-03 1983-11-29 Eli Lilly And Company Antiestrogenic and antiandrugenic benzothiophenes
DE69624813T2 (de) * 1995-06-23 2003-09-11 Advanced Life Sciences Inc., Lemont Robustaflavon und dessen derivate als antivirales mittel
US5998402A (en) * 1996-04-19 1999-12-07 American Home Products Corporation 2-phenyl-1-[4-(2-aminoethoxy)-benzyl]-indoles as estrogenic agents
US5919808A (en) * 1996-10-23 1999-07-06 Zymogenetics, Inc. Compositions and methods for treating bone deficit conditions
US5948776A (en) * 1996-10-23 1999-09-07 Zymogenetic, Inc. Compositions and methods for treating bone deficit conditions
US6331562B1 (en) * 1998-12-30 2001-12-18 Signal Pharmaceuticals, Inc. Compounds and methods for modulation of estrogen receptors
EP1173164A2 (en) * 1999-04-16 2002-01-23 AstraZeneca AB Estrogen receptor-beta ligands
AU2002221239A1 (en) * 2000-12-07 2002-06-18 Astrazeneca Ab Therapeutic benzimidazole compounds
JP2004524289A (ja) * 2000-12-22 2004-08-12 アストラゼネカ・アクチエボラーグ 治療化合物
WO2002056969A2 (en) * 2001-01-18 2002-07-25 Acumen Manufacturing Limited 10k step exercise method and apparatus
BR0208165A (pt) * 2001-03-16 2004-03-30 Wyeth Corp Composições farmacêuticas e seus usos na terapia de reposição de estrogênio
US6559177B2 (en) * 2001-04-19 2003-05-06 Wyeth 5, 11-Dioxa-benzo[b]fluoren-10-one and 5-oxa-11-thia-benzo[b]fluoren-10-ones as estrogenic agents
UA83620C2 (ru) * 2001-12-05 2008-08-11 Уайт Замещенные бензоксазолы и их аналоги как эстрогенные агенты
SE0202429D0 (sv) * 2002-08-14 2002-08-14 Astrazeneca Ab Novel Compounds

Also Published As

Publication number Publication date
RU2007105232A (ru) 2008-10-20
ECSP077279A (es) 2007-03-29
BRPI0514628A (pt) 2008-06-17
WO2006026316A2 (en) 2006-03-09
TW200612925A (en) 2006-05-01
AR050618A1 (es) 2006-11-08
US20060046968A1 (en) 2006-03-02
CL2008000506A1 (es) 2008-06-13
SV2006002205A (es) 2006-09-14
CN101044126A (zh) 2007-09-26
NO20071159L (no) 2007-03-26
US20080255057A1 (en) 2008-10-16
EP1781628A2 (en) 2007-05-09
MX2007002251A (es) 2007-04-20
GT200500228A (es) 2006-06-22
PE20060503A1 (es) 2006-07-20
AU2005280178A1 (en) 2006-03-09
NI200700055A (es) 2008-02-27
CA2576353A1 (en) 2006-03-09
JP2008510827A (ja) 2008-04-10
WO2006026316A3 (en) 2006-05-26
KR20070046148A (ko) 2007-05-02
IL181236A0 (en) 2007-07-04

Similar Documents

Publication Publication Date Title
CR8931A (es) Benzoxazoles sustituidos con profarmaco como agentes estrogenicos
ECSP045133A (es) Benzoxazoles sustituidos y análogos como agentes estrogenicos
ECSP056167A (es) Fenil quinolinas y su uso como agentes estrogénicos
BRPI0814267A2 (pt) Agentes citotóxicos compreendendo novos derivados de tomaicmicina e o seu uso terapêutico.
AR061446A1 (es) Utilizacion de la 1,7 -dimetilxantina para la fabricacion de un medicamento psicoanaleptico no ansiogeno destinado al tratamiento de un trastorno neuropsiquiatrico
GT200900283A (es) "terapia de combinación con un compuesto actuando como un inhibidor del receptor adp plaquetario".
DK1981889T3 (da) Cytotoksiske midler, der omfatter nye tomaymycin-derivater, og terapeutisk anvendelse deraf
HN2006007884A (es) Derivados de oxiindol
CR10712A (es) Derivados de quinazolinona 5-sustituidos como agentes antitumorales
CR20110188A (es) Combinacion de una insulina y un agonista de glp-1
CL2008002540A1 (es) Compuestos derivados aza-indol-2,3-sustituidos; composicion farmaceutica; y uso ene l tratamiento de una infeccion viral.
CR8744A (es) Compuestos terapeuticos
NO20081788L (no) Cyklopropylaminer som modulatorer av histamin-H3-reseptoren
MX2012005994A (es) Compuestos de 2-piridona.
CR7684A (es) Derivados de heterobiarilo como inhibidores de metaloproteinas de la matriz
CL2008002049A1 (es) Compuestos derivados de aminoindol macrociclicos; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de la hepatitis c.
AR059444A1 (es) Composiciones ramnolipidicas y metodos de uso relacionados
CR10603A (es) Derivados de 5,6-bisaril-2-piridin-carboxamida, su preparacion y su aplicacion en terapeutica como antagonistas de los receptores de urotensina ii
ECSP099566A (es) Sal napadisilato de un antagonista muscarínico m3
DE602007004999D1 (de) 1,4,5,6,7,8-hexahydro-1,2,5-triaza-azulen-derivate als orexinrezeptor-antagonisten
CL2007000595A1 (es) Compuestos derivados de piperidina; composicion farmaceutica y uso para el tratamiento y/o profilaxis de enfermedades seleccionadas entre hipertension, insuficiencia cardiaca congestiva e insuficiencia renal entre otras.
EA200702529A1 (ru) Фунгицидная комбинация биологически активных веществ
ECSP10010168A (es) Benzotiazolas como moduladores del receptor de ghrelina
BRPI0807804A2 (pt) " arilciclopentenos substituídos como agentes terapêuticos ".
UY30121A1 (es) Nuevos compuestos

Legal Events

Date Code Title Description
FA Abandonment or withdrawal (granting procedure)